Su et al. demonstrated that increasing the expression of miR-135b in drug-resistant non-small cell lung cancer (NSCLC) cells enhanced their sensitivity to CIS treatment by directly downregulating Frizzled-1 (FZD1) [176]. Here, FZD1 is linked to in situ carcinoma.